Malignant Pleural Mesothelioma, AdvancedPhase 2NCT03786419
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
A Phase 2 study testing Atezolizumab in people with Malignant Pleural Mesothelioma, Advanced and Malignant Pleural Mesothelioma, Unresectable, run by Health Pharma Professional Research at 1 site in Mexico.
Trial summary
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Pleural Mesothelioma, Advanced, Malignant Pleural Mesothelioma, Unresectable
- What is being tested?
- Atezolizumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteMexico
- Study dates
- Aug 2020to Aug 2020
- Phase
- Phase 2
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Signed informed consent form.
- Patients have ≥18 years of age.
- Diagnosis of malignant pleural mesothelioma histologically confirmed by certified pathologist.
- Unresectable and/or advanced disease, based on the Seventh Edition American Joint Committee on Cancer (AJCC) Cancer Staging Manual. Patients with MPM diagnosed with early disease and whose comorbidities make them ineligible for surgical procedures or who do not accept surgery treatment.
- Patients should have received at least one platinum-based treatment and should have reported progression after at least two treatment cycles.
- Disease measurable as per the Response Evaluation Criteria in Solid Tumors (RECIST) modified for mesothelioma.
Show all 12Show fewer
- ECOG performance status ≤2.
- >12-week life expectancy.
- Patients with adequate organ function
- Patients should have recovered to grade ≤1 in all adverse events associated with previous antineoplastic therapies, excluding alopecia.
- Patients should be able to comply with protocol procedures, at the discretion of the investigator
- Patients of both genders who are potentially fertile should use effective contraceptive methods (barrier methods plus other contraceptive methods) before study entry and during their participation in the study.
Who cannot join
- Patients diagnosed with another tumor, except for treated cervical carcinoma in situ, epidermoid carcinoma, or superficial bladder cancer (Ta and Tis), or other malignancy for which healing therapy was administered within 5 years before study enrollment.
- Simultaneous participation in another study on a study drug, or if the patient participated in a study within 28 days before study treatment initiation.
- Medical history of interstitial lung disease (ILD), drug-induced interstitial disease, radiation pneumonitis that required treatment with steroids, or any sign of clinically active interstitial lung disease.
- Use of systemic immunosuppressive therapy (use of steroids with a dose >10 mg of prednisone or other immunosuppressive therapy).
- Presence of active autoimmune disease.
- Suspicion or certainty of symptomatic brain metastasis or spinal cord compression. Patients with asymptomatic and stable brain metastasis are eligible for the study.
Show all 15Show fewer
- Pregnant or breastfeeding women. Women of childbearing potential must have a negative pregnancy test carried out within 7 days prior to treatment initiation.
- Patient previously treated with immunotherapy (PD-1/PD-L1 inhibitors).
- Major surgery within 4 weeks prior to study treatment initiation or expected major surgery during the course of the study for non-diagnostic purposes.
- Known seropositivity for human immunodeficiency virus (HIV). tory or symptoms of HIV may enter the study only if there is negative serology.
- Active tuberculosis.
- Administration of a live attenuated vaccine within 4 weeks prior to study treatment initiation or at any moment during the course of the study.
- Last chemotherapy cycle within 30 days prior to first treatment administration.
- Any unstable disease or condition that may threaten the patient's safety and/or the patient's study compliance.
- Drug addiction or clinical, psychological, or social disorders that may undermine the informed consent validity or affect compliance with protocol.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Phase II Study to Evaluate the Efficacy and Safety of Atezolizumab in Subjects With Unresectable or Advanced Malignant Pleural Mesothelioma Who Experienced Progression on Platinum-Based Chemotherapy
This is a national, single arm, phase II trial in patients with diagnosis of unresectable or advanced malignant pleural mesothelioma who experienced progression after platinum-based chemotherapy.
Read the detailed description
The study includes a screening period a treatment period, a termination treatment visit ≤30 days following the last dose of the study drug, and a follow-up period. Day 1 is defined as the first day in which patients receive atezolizumab. The study is expected to enroll 36 patients.
Enrolled patients will receive a fixed dose of atezolizumab 1200 mg administered intravenously the first day of each cycle. A treatment cycle will last 21 days (± 3 days). Treatment with atezolizumab will continue until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
Treatment with atezolizumab may continue while patients experience clinical benefit based on the investigator's assessment (absence of unacceptable toxicity or symptomatic deterioration attributable to disease progression, at the discretion of the investigator after evaluating radiographic data, biopsy results [if available], and clinical status), or until unacceptable toxicity or death.
During treatment, patients treated with atezolizumab, who demonstrate evidence of clinical benefit may continue treatment with atezolizumab after meeting disease progression criteria, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The following need to be met, as specified by the protocol.
All patients must undergo tumor assessments at baseline and every 9 weeks (± 7 days) following cycle 1, day 1, regardless of treatment delays, until radiographic disease progression, as per RECIST v1.1 modified for mesothelioma, or loss of clinical benefit in patients treated with atezolizumab, who continue treatment beyond disease progression, as per RECIST v1.1, withdrawal of consent, death or study termination by principal investigator, whichever occurs first.
The study will end if all enrolled patients die, withdraw their consent, become lost to follow-up, or have been monitored during 12 months from the enrollment of the last patient, whichever occurs first.
- Being tested
- Atezolizumab
- Keywords
- Malignant Pleural Mesothelioma, Atezolizumab, Thoracic neoplasms, Antibodies, monoclonal, Antineoplasic, agents
- Medical subject headings
- Mesothelioma, Malignant, Thoracic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AtezolizumabDrug
Also called Tecentriq, RO5541267, MPDL3280A
Participants will be given 1200 mg of Atezolizumab as single agent by IV infusion every 21 days. First infusion will be over 60 min. Subsequent Atezolizumab cycles may be administered for 30 minutes, if there were no perfusion-related toxicity
| Study group | Role | What they receive |
|---|---|---|
| Atezolizumab | Experimental | Participants with unresectable or advanced malignant pleural mesothelioma who have progressed after platinum-based chemotherapy will receive atezolizumab 1200 mg every 21 days, until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first). Receives: Drug: Atezolizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Objective Response Rate
The number of subjects whose best confirmed objective response is a CR or PR, divided by the number of treated subjects
Measured: From the time of initial response until documented tumor progression or death, whichever occurs first (up to approximately 4 years)
Secondary outcomes (6)
Progression-free survival
The time from the date of the start of treatment to the date of the first documented tumor progression as determined by RECIST v 1.1, or death, whichever occurs first
Measured: Baseline up to disease progression or death, whichever occurs first (up to approximately 4 years)
Duration of response
The time from documentation of tumor response to disease progression as determined by RECIST v1.1
Measured: Baseline up to disease progression or death, whichever occurs first (up to approximately 4 years)
Overall survival
The time from the date of the start of treatment until death from any cause
Measured: Baseline up to 1 year after treatment discontinuation
Safety of atezolizumab
The incidence of treatment-related adverse events assessed by CTCAE v4.03
Measured: Baseline up to 60 days after the last dose of the study drug or until another oncologic treatment is initiated, whichever occurs first
Health Related Quality of Life (HRQoL) Scores
Change from Baseline in Health Related Quality of Life (HRQoL) Scores as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - C30 (EORTC QLQ-C30)
Measured: Baseline until 1 year after treatment discontinuation or death, whichever occurs first
Patient Functioning and Symptoms Score
Change from Baseline in Patient Functioning and Symptoms Score as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module LC-13 (QLQ-LC13)
Measured: Baseline until 1 year after treatment discontinuation or death, whichever occurs first
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2018
- Study startAug 2020 (estimated)
- Primary completionAug 2020 (estimated)
- Study completionAug 2020 (estimated)
Why it stopped: Publication of study results of ICI use in MPM as first line therapy
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Pleural Mesothelioma, AdvancedStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Health Pharma Professional Research
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jorge Arturo Alatorre Alexander, Health Pharma Professional Research
- Investigators
- Jorge Arturo Alatorre Alexander, MD, Principal investigator, Health Pharma Professional Research
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03786419
- Sponsor's protocol ID
- JCJ-768883
- Status last verified
- May 2021
- First submitted
- 18 Dec 2018
- Last updated
- 13 May 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No